Red blood cells from pluripotent stem cells for use in transfusion.
Red blood cells from pluripotent stem cells for use in transfusion.
复制标题
DOI：
10.2217/rme.10.22
复制
发表时间：
2010-05
影响因子：
2.7
通讯作者：
J. Mountford;Emmanuel N Olivier;N. Jordanides;P. D. De Sousa;M. Turner
中科院分区：
文献类型：
--
作者：
J. Mountford;Emmanuel N Olivier;N. Jordanides;P. D. De Sousa;M. Turner
在输血中使用捐赠的红细胞是一种行之有效的细胞疗法。然而，即使是最好的服务，供应不足、输血传播感染和免疫匹配需求等问题也阻碍了这一进程。通过使用多能干细胞生成通用供体 O 组、恒河猴 D 阴性红细胞，可以消除这些问题。人类胚胎干细胞可以无限期地维持和扩增，因此可以产生该应用所需的大量细胞。红细胞的产生也是多能干细胞衍生疗法的一个有吸引力的目标，因为它是一种特征良好的单细胞悬浮液，缺乏有核细胞并且 HLA 分子表达低。已经取得了很大进展；然而，仍然存在一些挑战，包括扩大规模、临床有效性和产品安全性。
The use of donated red blood cells in transfusion is a well-established cellular therapy. However, problems including insufficient supply, transfusion-transmitted infections and the need for immunological matching hamper even in the best services. These issues may be eliminated by using pluripotent stem cells to generate universal donor group O, Rhesus D-negative red blood cells. Human embryonic stem cells can be maintained and expanded indefinitely and can, therefore, produce the very large cell numbers required for this application. Red blood cell production is also an attractive goal for pluripotent stem cell-derived therapeutics because it is a well-characterized single cell suspension, lacking nucleated cells and with a low expression of HLA molecules. Much progress has been made; however, a number of challenges remain including scale-up, clinical effectiveness and product safety.